We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
Humacyte, Inc. (HUMA - Free Report) ended the recent trading session at $0.84, demonstrating a +2.66% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 1.02% for the day. On the other hand, the Dow registered a gain of 1.62%, and the technology-centric Nasdaq increased by 0.89%.
Shares of the company witnessed a gain of 38.54% over the previous month, beating the performance of the Medical sector with its loss of 1.69%, and the S&P 500's gain of 12.23%.
The upcoming earnings release of Humacyte, Inc. will be of great interest to investors. The company is expected to report EPS of -$0.1, unchanged from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1.23 million, indicating a 136.54% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.39 per share and a revenue of $8.83 million, representing changes of -50% and +333.02%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Humacyte, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 11.36% upward. As of now, Humacyte, Inc. holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 144, this industry ranks in the bottom 41% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing
Humacyte, Inc. (HUMA - Free Report) ended the recent trading session at $0.84, demonstrating a +2.66% change from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 1.02% for the day. On the other hand, the Dow registered a gain of 1.62%, and the technology-centric Nasdaq increased by 0.89%.
Shares of the company witnessed a gain of 38.54% over the previous month, beating the performance of the Medical sector with its loss of 1.69%, and the S&P 500's gain of 12.23%.
The upcoming earnings release of Humacyte, Inc. will be of great interest to investors. The company is expected to report EPS of -$0.1, unchanged from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1.23 million, indicating a 136.54% upward movement from the same quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.39 per share and a revenue of $8.83 million, representing changes of -50% and +333.02%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for Humacyte, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 11.36% upward. As of now, Humacyte, Inc. holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 144, this industry ranks in the bottom 41% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.